Alexandra Dambeck

Alexandra Dambeck is a senior German finance executive. She joined Springer Nature in January 2024 as Chief Financial Officer and member of the Management Board, succeeding Dr. Ulrich Vest. Springer Nature said she joined from Fresenius Medical Care, where she had spent more than twenty years in finance leadership roles across the global healthcare group.

At Fresenius Medical Care, Dambeck held roles including responsibility for Finance and Accounting in Europe, Efficiency Programs in the U.S., CFO roles for Global Research & Development and Manufacturing & Supply Chain, and most recently Executive Vice President, Head of Corporate Controlling & Corporate Accounting. SEC filings also list her as an executive contact for Fresenius Medical Care and as a signatory with that EVP title in 2023.

Before Fresenius Medical Care, Dambeck began her career at KPMG and worked at Dyckerhoff, where Dürr’s 2026 appointment release says she worked in investment controlling. Dürr also states that she holds a degree in business administration.

In January 2026, Dambeck became Managing Director of Springer Fachmedien Wiesbaden GmbH while continuing as Springer Nature CFO. On May 21, 2026, Dürr AG announced that she had been appointed to its Board of Management and would become CFO on November 15, 2026, with responsibility for Finance, Investor Relations, Legal Affairs, Sustainability, and Information Technology.

• Public evidence of Dambeck as an investor is limited. The main public investor-directory listing identifies her as an angel investor focused on Seed Round investments.
• The same directory lists her industry focus as Health & Wellness and describes her areas of interest as dialysis, hemodialysis, and home dialysis.
• No primary-source personal investment thesis, check size, portfolio list, or public statement of angel-investing criteria was found.
• Her operating background is strongest in healthcare, renal care, global finance, accounting, controlling, manufacturing, R&D finance, capital markets, and public-company governance.
• For founder fit, the most defensible angle is a healthcare or medical-technology company where her Fresenius Medical Care experience, finance leadership, and dialysis-sector exposure are directly relevant.